

Literaturverzeichnis

Hamburger Ärzteblatt 06/07 | 2022

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 16: Neue Behandlungskonzepte bei aggressiven Lymphomen. *Von Prof. Dr. Ahmet Elmaagacli, PD Dr. Christian Jehn*

1. McLaughlin P et al. Rituximab chimeric anti- CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four- dose treatment program. *J. Clin Oncol* 1998, 16: 2825–2833.
2. Vitolo U, Trneny M, Belada D et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2017; 35: 3529–3537.
3. Duell J, Maddocks KJ, González-Barca E et al. Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. *Haematologica* 2021, 106: 2417.
4. Advani R, Flinn I, Popplewell L et al. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. *N. Engl. J. Med.* 2018, 379: 1711–1721.
5. Sehn LH, Herrera AF, Flowers CR et al. Polatuzumab Vedotin in Re-lapsed or Refractory Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2020, 38: 155–165.
6. Tilly H, Morschhauser F, Sehn LH et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. *N Engl J Med* 2022, 386(4):351-363.
7. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science.* 2018, 359: 1350–1355.
8. Hodi FS et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N. ngl J Med* 2010, 363: 711–723.
9. Vokes EE et al. Nivolumab versus docetaxel in previously treated advanced non- small- cell lung cancer (CheckMate 017 and CheckMate 057): 3- year update and outcomes in patients with liver metastases. *Ann Oncol* 2018, 29: 959–965.
10. Reck M et al. Pembrolizumab versus chemotherapy for PD- L1- positive non- small- cell lung cancer. *N Engl J Med* 2016, 375: 1823–1833.
11. Garon EB et al. Pembrolizumab for the treatment of non- small- cell lung cancer. *N Engl J Med*, 2015, 372: 2018–2028.
12. Sharma P et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open- label, two- stage, multi- arm, phase 1/2 trial. *Lancet Oncol* 2016, 17:1590–1598.
13. Kao, H-F, Lou P-J. Immune checkpoint inhibitors for head and neck squamous cell carcinoma: current landscape and future directions. *Head Neck* 41, 4–18 (2019).
14. Hizal M et al. A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. *Curr Med Res Opin* 2020, <https://pubmed.ncbi.nlm.nih.gov/31942809/>.
15. Zhang X et al. Safety and efficacy in relapsed or refractory classic Hodgkin's lymphoma treated with PD-1 inhibitors: a meta- analysis of 9 prospective clinical trials. *BioMed Res Int* 2019, 9283860.
16. Menter T, Bodmer-Haecki A, Dirnhofer S, Tzankov A. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas. *Hum Pathol* 2016, 54: 17–24.
17. Staerz UD, Kanagawa O, Bevan MJ. Hybrid antibodies can target sites for attack by Tcells. *Nature* 1985, 314: 628–631.
18. Salvaris R, Ong J, Gareth PG. Bispecific antibodies: A Review of Development, ClinicalEfficacy and Toxicity in B-Cell-Lymphomas. *J Pers Med* 2021, 11:355.
19. Modi D, Potugari N, Uberti J. Immuntherapy for Diffuse Large B-Cell Lymphoma: CurrentLandscape and Future Directions. *Cancers* 2021, 13: 5827.
20. Goebeler ME, Bargau RC. T cell-engaging therapies-BiTEs and beyond. *Nat Rev ClinOncol* 2020, 17(7):418-434.
21. Brinkmann U, Kontermann RE. The making of bispecific antibodies. *mAbs* 2017, 9: 182–212.

Literaturverzeichnis

Hamburger Ärzteblatt 06/07 | 2022

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

22. Ruf P et al. Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. *Br J Clin Pharmacol* 2010, 69: 617–625.
23. Viardot A, Goebeler ME, Hess G et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. *Blood* 2016, 127: 1410–1416.
24. Goebeler ME, Knop S, Viardot A et al. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study. *J Clin Oncol*, 2016, 34: 1104–1111.
25. Coyle L, Morley NJ, Rambaldi A et al. Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Leuk Lymphoma* 2020, 61.
26. Hutchings M, Morschhauser F, Iacoboni G et al. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial. *J Clin Oncol* 2021, 39: 1959–1970.
27. Budde LE, Ghosh N, Chavez JC et al. Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab with polatuzumab vedotin in patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). *J. Clin. Oncol.* 2021, 39: 7520.
28. Clausen MR, Lugtenburg P, Hutchings M et al. Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity. *J Clin Oncol.* 2021, 39: 7518.
29. Bannerji MR, Allan JN, Arnason JE et al. Odronektamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CART Therapy. *Blood* 2020, 136: 42–43.
30. Tran E, Longo DL, Urba WJ. A Milestone for CAR T Cells. *N Engl J Med.* 2017, 28; 377(26): 2593-2.
31. Locke FL, Ghobadi A, Jacobson CA et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial. *Lancet Oncol.* 2019, 20: 31–42.
32. Schuster SJ, Bishop MR, Tam CS et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N. Engl. J. Med.* 2019, 380, 45–56. 596. doi: 10.1056/NEJMe1714680.
33. Locke FL, Miklos DB, Jacobson CA et al. All ZUMA-7 Investigators and Contributing Kite Members. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. *N Engl J Med.* 2022;386(7):640-654. doi: 10.1056/NEJMoa2116133.
34. Kamdar, Manali et al. Lisocabtagene Maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma: results from the randomized phase 3 transform study." *Blood* 138 (2021): 91.
35. Bishop MR et al. Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed aggressive B-cell non-Hodgkin lymphoma: analysis of the phase III Belinda study." *Blood* 138 (2021): LBA-6.
36. Lee DW, Santomaso BD, Locke FL et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. *Biol. Blood Marrow Transplant.* 2019, 25: 625–638.

Angaben zu möglichen Interessenkonflikten: vorhanden

Ahmet Elmaagacli und Christian Jehn:

Honorare: AbbVie, Pfizer, Amgen, Rache, BMS, Incyte, Novartis, Sanofi, Kite/Gilead, Celgene

Reisekostenerstattung: Janssen, Amgen, Celgene, BMS, Janssen, Kite/Gilead, AbbVie

Literaturverzeichnis

Hamburger Ärzteblatt 06/07 | 2022

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 26 – 28: Moderne Wundbehandlung. *Von Hauke Cornelsen*

1. Földi M, Strößenreuther R. Grundlagen der manuellen Lymphdrainage. 4. Aufl. URBAN & FISCHER Verlag. 2014;5:38.
2. Hepp W, Gussmann A, Brunner UV. Lymphologische Gesichtspunkte in der Gefäßchirurgie: Manuelle Maßnahmen rund um die Wundheilung aus lymphologischer Sicht. Steinkopf Verlag. 2006;59.
3. Moysidis T. Das venöse Ulkus ist eine ischämische Wunde. MMW-Fortschritte der Medizin. 2012;154:73-76 (Suppl. 03).
4. Dissemmond J. Ulcus cruris – Fachbuch. Genese Diagnostik und Therapie Uni-Med Verlag, 2005.
5. Meyne K. Handbuch Arterielle Verschlusskrankheit: Stadienabhängige Indikation der Basistherapie. Schlütersche GmbH & Co. KG Verlag. 2003;81.
6. Deutsche Gesellschaft für Wundheilung und Wundbehandlung e.V. DGfW. www.dgfw.de
7. Kommission für Krankenhaushygiene und Infektionsprävention beim Robert Koch-Institut. Infektionsprävention in Heimen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2005
8. Münter KC. Fortschritte in der modernen Wundversorgung. Uni-Med Verlag. 2010;6.7:67.
9. S3 -Leitlinie Lokalthherapie chronischer Wunden bei Patienten mit Risiken periphere arterielle Verschlusskrankheit, Diabetes mellitus, chronische venöse Insuffizienz: www.awmf.org/leitlinien/detail/II/091-001.html
www.awmf.org/uploads/tx_szleitlinien/091-001I_S3_Lokalthherapie_chronischer_Wunden_2012-ungueltig.pdf
10. Büscher A. Expertenstandard Pflege von Menschen mit chronischen Wunden. Aus: Deutsches Netzwerk für Qualitätsentwicklung in der Pflege. 1. Aktualisierung 2015.

Angaben zu möglichen Interessenkonflikten: keine

S. 30 – 31: Der besondere Fall: Revaskularisation eines V. cava superior Stents.

Von Prof. Dr. Axel Wetter, Kai-Uwe Wagenhofer, Prof. Dr. Walter Gross-Fengels

1. Klein-Weigel PF, Elitok S, Ruttloff A et al. Superior vena cava syndrome. Vasa 2020; 49, 437-448.
2. Friedman T, Quencer KB, Kishore SA, Winolur RS, Madoff DC. Malignant venous obstruction: Superior vena cava syndrome and beyond. Semin Intervent Radiol 2017; 34: 398-408.
3. Watkinson AF, Yeow TN, Fraser C. Endovascular stenting to treat obstruction of the superior vena cava. BMJ 2008; 336: 1434 -1437.
4. Fagedet D, Thony F, Timsit JF et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent radiol 2013; 36: 140-149.
5. Beecham Chick JF, Abramowitz SD, Osher ML et al. Radiographic findings of distressed venous stents and inferior vena cava filters: clinical implications. AJR 2017; 209: 1150-1157.

Angaben zu möglichen Interessenkonflikten: keine

S. 32: Stellungnahme zum Leserbrief „Universitätsmedizin – quo vadis?“ von Dr. Henning Harder

Von PD Dr. Christina Magnussen

1. Chandra A, Lewis EF, Claggett BL et al. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. JAMA Cardiol 2018;3:498-505.
2. Voors AA, Angermann CE, Teerlink JR et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568-74.

Literaturverzeichnis

Hamburger Ärzteblatt 06/07 | 2022

Seite 4

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

3. McDonagh TA, Metra M, Adamo M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *European heart journal* 2021;42:3599-726.
4. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *European heart journal* 2016;37:2129-200.
5. McMurray JJ, Packer M, Desai AS et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. *The New England journal of medicine* 2014;371:993-1004.
6. Cannon JA, Shen L, Jhund PS et al. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. *European journal of heart failure* 2017;19:129-37.
7. Perlman A, Hirsh Raccach B, Matok I, Muszkat M. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database. *J Card Fail* 2018;24:533-6.
8. De Vecchis R, Ariano C, Di Biase G, Noutsias M. Cognitive performance of patients with chronic heart failure on sacubitril/valsartan : A retrospective cohort study. *Herz* 2019;44:534-40.
9. Zannad F, Ferreira JP, Pocock SJ et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. *Lancet* 2020;396:819-29.
10. Tromp J, Ouwerkerk W, van Veldhuisen DJ et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. *JACC Heart Fail* 2022;10:73-84.

S. 33: Bilder aus der klinischen Medizin: Implantation eines schrägen Venenstents bei Venensporn (May-Thurner-Syndrom) *Von Prof. Dr. Sigrid Nikol, Dr. Ralf Weser*

Video zum Beitrag:

Langsame Freisetzung eines Optimed Sinus-Obliquus-Venenstents in die linke VIC:

https://www.aerztekammer-hamburg.org/files/aerztekammer_hamburg/ueber_uns/hamburger_aerzteblatt/archiv/haeb2022/video_haeb_062022_sinus_obliquus.mp4

Literatur:

1. Stuck AK, Kunz S, Baumgartner I, Kucher N. Patency and Clinical Outcomes of a Dedicated, Self-Expanding, Hybrid Oblique Stent Used in the Treatment of Common Iliac Vein Compression. *J Endovasc Ther.* 2017 Feb;24(1):159-166. doi: 10.1177/1526602816676803. Epub 2016 Nov 10. PMID: 27831483.
2. Sebastian T, Lichtenberg M, Schlager O, Jalaie H, de Graaf R, Erbel C, Massmann A, Schindewolf M, Grigorean A, Kucher N. Early clinical outcomes for treatment of post-thrombotic syndrome and common iliac vein compression with a hybrid Oblique self-expanding nitinol stent - the TOPOS study. *Vasa.* 2020 Jun;49(4):301-308. doi: 10.1024/0301-1526/a000857. Epub 2020 Apr 6. PMID: 32248759.